DRUG · Mapped RxNorm record
Irbesartan
Normalized identity: irbesartanView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria
NCT00561964
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedRandomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Hypertensionunresolved
Interventions
IrbesartanDRUG · verified · RxNorm: irbesartan
placeboDRUG
Sponsors & collaborators
Sanofilead sponsor
Bristol-Myers Squibbcollaborator
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00561964 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.